It has also been shown that GLP-1 RAs not only act by modulating the cytokines involved in IBD but also act on innate lymphoid type 3 cells (ILC3), which are involved in defence against pathogens and repair of the intestinal mucosa. Here, GLP1R is linked to inflammatory bowel disease.